BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27081859)

  • 1. Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
    Tan GS; Leon PE; Albrecht RA; Margine I; Hirsh A; Bahl J; Krammer F
    PLoS Pathog; 2016 Apr; 12(4):e1005578. PubMed ID: 27081859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
    Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
    Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
    Henry Dunand CJ; Leon PE; Huang M; Choi A; Chromikova V; Ho IY; Tan GS; Cruz J; Hirsh A; Zheng NY; Mullarkey CE; Ennis FA; Terajima M; Treanor JJ; Topham DJ; Subbarao K; Palese P; Krammer F; Wilson PC
    Cell Host Microbe; 2016 Jun; 19(6):800-13. PubMed ID: 27281570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans.
    Li M; Chen L; Wang Q; Hao M; Zhang X; Liu L; Yu X; Yang C; Xu J; Chen J; Gong R
    Antiviral Res; 2019 Oct; 170():104556. PubMed ID: 31299269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
    Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation.
    Wang Y; Lv Y; Niu X; Dong J; Feng P; Li Q; Xu W; Li J; Li C; Li J; Luo J; Li Z; Liu Y; Tan YJ; Pan W; Chen L
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32796071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
    Kirkpatrick E; Henry C; McMahon M; Jiang K; Strohmeier S; van Bakel H; Wilson PC; Krammer F
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32907980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
    Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
    J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus.
    Yang F; Xiao Y; Lu R; Chen B; Liu F; Wang L; Yao H; Wu N; Wu H
    Emerg Microbes Infect; 2020; 9(1):664-675. PubMed ID: 32193996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent H7 immunogens offer protection from H7N9 virus challenge.
    Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
    J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.
    Krammer F; Jul-Larsen A; Margine I; Hirsh A; Sjursen H; Zambon M; Cox RJ
    Clin Vaccine Immunol; 2014 Aug; 21(8):1153-63. PubMed ID: 24943383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
    Schmeisser F; Vasudevan A; Verma S; Wang W; Alvarado E; Weiss C; Atukorale V; Meseda C; Weir JP
    PLoS One; 2015; 10(1):e0117108. PubMed ID: 25629172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of H7N9 hemagglutinin novel protein epitopes that elicit strong antibody-dependent, cell-mediated cytotoxic activities with protection from influenza infection in mouse model.
    Zhu P; Yi X; Zhang L; Liu Y; Wang S; Gu J; Zhu X; Yu X
    Cell Immunol; 2021 Jan; 359():104255. PubMed ID: 33316647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
    Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
    J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection Against H7 Subtype Influenza Virus Infection in Mice by Passive Transfer of Neutralizing Monoclonal Antibody.
    Zhang Z; Liu M; Zheng S
    Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):360-5. PubMed ID: 26492625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.
    Wang TT; Tan GS; Hai R; Pica N; Petersen E; Moran TM; Palese P
    PLoS Pathog; 2010 Feb; 6(2):e1000796. PubMed ID: 20195520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
    Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P
    J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.